News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Pharmatech, Inc. Contracts for Five New Just-in-Time Clinical Trials New JIT Enrollment Program Speeds Oncology Patient Accrual


7/25/2008 7:30:24 AM

DENVER, July 24 /PRNewswire/ -- Pharmatech, Inc., a Research Management Organization (RMO), has contracted with five leading pharmaceutical companies to provide research and site management services for their clinical trials using the Just-in-Time (JIT) enrollment strategy. The new trials include the following disease indications: follicular Non-Hodgkin's Lymphoma, Metastatic Breast Cancer, Metastatic Sarcoma, Chronic Myelogenous Leukemia, and Non-Small Cell Lung Cancer (NSCLC).

Pharmatech will manage the trials using its innovative JIT approach. This streamlined approach was created to increase enrollment in oncology clinical trials. This patient first initiative allows for identification of cancer patients through basic standard of care procedures, so the site opens only if the patient qualifies for the study. Patient enrollment increases because a protocol is rolled out to a large number of qualified Research Network sites with minimal expense of time and capital for both the sites and sponsors.

The new oncology clinical trials are targeted to achieve enrollment of over 500 cancer patients with the participation of approximately 165 Pharmatech Research Network sites. Matthew Wiener, Pharmatech CEO, states that "The recent activity in new business has been a true testament to the acceptance of the Just-In-Time enrollment strategy. Study sponsors and sites have praised the new enrollment methodology, as cancer patients are treated in a more efficient manner and sponsors see their trials completed in a shorter time frame."

About Pharmatech, Inc.:

Pharmatech, headquartered in Denver, Colorado, is a Research Management Organization (RMO) dedicated to the highest quality of clinical research. Pharmatech provides services of a Site Management Organization (SMO) and a Contract Research Organization (CRO) with a focus in oncology clinical trials. Through an organized research network, the Company focuses on the development and utilization of therapeutic products among sponsors, investigators, and patients. For more information about Pharmatech, please visit http://www.pharmatech.com.

Key Words: Oncology, Clinical Trials, Cancer Patients, CRO, SMO, Lymphoma, Leukemia, Breast Cancer, Lung Cancer, Sarcoma, Just-In-Time

CONTACT: Kristi Pohly, Marketing Manager of Pharmatech, +1-720-917-8400,
kristip@pharmatech.com

Web site: http://www.pharmatech.com/


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES